by EpicentRx | Feb 15, 2023 | 2023, Press Releases
TORREY PINES, Calif., February 15, 2023 — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced that it has been selected for a...
by EpicentRx | Feb 10, 2023 | Blog
It may seem belated to ask, given that we are now in February, but for Christmas, were you naughty or nice? For the small molecule, RRx-001, the answer was (and is) both. Under inflammatory and low oxygen or hypoxic conditions, which are present almost exclusively in...
by EpicentRx | Feb 9, 2023 | Conferences
January 2023, San Francisco, California Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001 Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001 Using correlative studies for measuring...
by EpicentRx | Feb 9, 2023 | Conferences
January 2023, San Francisco, California Poster: Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
by EpicentRx | Feb 9, 2023 | Conferences
December 2022, San Antonio, Texas Poster: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial
